rs16950650 in ABCC4 gene and Non-Small Cell Lung Carcinoma

PMID 23478653 2014 A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.

rs778561687 in AKT2 gene and Non-Small Cell Lung Carcinoma

PMID 21479466 2012 AKT1 and AKT2 mutations in lung cancer in a Japanese population.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs41997 in ANKRD7 gene and Non-Small Cell Lung Carcinoma

PMID 22872573 2012 The minor allele of three SNPs (rs7629386 at 3p22.1, rs969088 at 5p14.1, and rs3850370 at 14q24.3) were associated with worse NSCLC survival while 2 (rs41997 at 7q31.31 and rs12000445 at 9p21.3) were associated with better NSCLC survival.

rs1200399 in BAZ1A gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs200595745 in BPTF gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs113488022 in BRAF gene and Non-Small Cell Lung Carcinoma

PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

PMID 14688025 2004 Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.

PMID 19593635 2010 Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

PMID 17314276 2007 Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 12460919 2002 Missense mutations of the BRAF gene in human lung adenocarcinoma.

PMID 15046639 2004 Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

PMID 14681681 2003 Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.

PMID 15035987 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

PMID 23093928 2012 A structural systems biology approach for quantifying the systemic consequences of missense mutations in proteins.

PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 22892241 2012 The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

PMID 15753399 2005 Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.

PMID 15016963 2004 High frequency of mutations of the PIK3CA gene in human cancers.

PMID 19383316 2008 Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

PMID 17119447 2006 NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

PMID 17311103 2007 B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.

PMID 18368129 2008 MC1R variants increase risk of melanomas harboring BRAF mutations.

PMID 17096326 2007 Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.

PMID 19913317 2010 KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

PMID 19794125 2009 Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

PMID 21716161 2011 BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.

PMID 21343559 2011 Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

PMID 19363522 2009 Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.

PMID 21190184 2011 Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.

PMID 22535154 2012 Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

rs10023113 in CAMK2D gene and Non-Small Cell Lung Carcinoma

PMID 25145502 2015 These findings suggest that CAMK2D rs10023113 may be a potentially prognostic marker for overall survival of early-stage NSCLC patients in Chinese population.

rs3769821 in CASP8 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs55781567 in CHRNA5 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs401681 in CLPTM1L gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs1878022 in CMKLR1 gene and Non-Small Cell Lung Carcinoma

PMID 21483023 2011 Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

rs56113850 in CYP2A6 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs1077424 in DAB1 gene and Non-Small Cell Lung Carcinoma

PMID 21866343 2012 The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.

rs5879422 in DCBLD1 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs1057519847 in EGFR gene and Non-Small Cell Lung Carcinoma

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 22622260 2012 Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.

PMID 18089823 2007 PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

PMID 17545553 2007 The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.

PMID 23800712 2013 Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.

PMID 16730855 2006 Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.

PMID 19147750 2009 Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

PMID 19455431 2010 In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.

PMID 15710947 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

PMID 16115929 2005 Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

PMID 15738541 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

PMID 22753918 2012 Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

PMID 15329413 2004 "EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."

PMID 19922469 2010 Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

PMID 23102728 2013 MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.

PMID 16011858 2005 Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

PMID 21531810 2011 "Effectiveness of tyrosine kinase inhibitors on ""uncommon"" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."

PMID 2302402 1990 Effects of marine oil-enriched diets on guinea pig megakaryocyte and platelet lipids: effects on thromboxane synthesis and platelet function.

PMID 20479403 2010 Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

PMID 15118125 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

PMID 15118073 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

PMID 23242437 2013 Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

PMID 23945392 2013 Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.

PMID 18458038 2008 First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

PMID 23485129 2013 Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.

PMID 19536777 2010 Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

PMID 18199554 2008 Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

PMID 15788655 2005 Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.

PMID 19671738 2009 Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.

PMID 21841502 2011 Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.

PMID 18450321 2008 Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.

PMID 16533793 2006 Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.

PMID 18176089 2007 Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.

rs121913432 in EGFR-AS1;EGFR gene and Non-Small Cell Lung Carcinoma

PMID 18628075 2008 A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 18372921 2008 EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.

PMID 16187797 2005 Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

PMID 21572125 2011 Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.

PMID 19096302 2009 Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

PMID 16533793 2006 Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.

rs121913465 in EGFR;EGFR-AS1 gene and Non-Small Cell Lung Carcinoma

PMID 15623594 2004 High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

PMID 19536777 2010 Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

PMID 16205628 2006 Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.

PMID 16863509 2006 EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 19147750 2009 Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

PMID 17653080 2008 EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.

PMID 20522446 2010 We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib.

PMID 16187797 2005 Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

PMID 20422446 2010 Comparing ICA-based and single-trial topographic ERP analyses.

PMID 17045698 2006 Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.

PMID 18676761 2008 Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

rs1656402 in EIF4E2 gene and Non-Small Cell Lung Carcinoma

PMID 21079520 2011 Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.

rs397516976 in ERBB2;MIR4728 gene and Non-Small Cell Lung Carcinoma

PMID 15457249 2004 Lung cancer: intragenic ERBB2 kinase mutations in tumours.

PMID 22761469 2012 Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

PMID 15753357 2005 Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

PMID 16863509 2006 EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

PMID 16825508 2006 Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.

PMID 16775247 2006 HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

rs7252463 in FCGBP gene and Non-Small Cell Lung Carcinoma

PMID 21866343 2012 The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.

rs1853837 in FOXP4-AS1 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs2517873 in HLA-A;MCCD1P1 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs112445441 in KRAS gene and Non-Small Cell Lung Carcinoma

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

PMID 19047918 2009 Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.

PMID 17062680 2006 Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.

PMID 21398618 2011 Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

PMID 17704260 2007 Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

PMID 22897852 2012 Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

PMID 21169357 2011 KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.

PMID 17332249 2007 Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

PMID 20609353 2010 A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

PMID 19358724 2009 KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

PMID 19029981 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

PMID 15842656 2005 Somatic PTPN11 mutations in childhood acute myeloid leukaemia.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 22235099 2012 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

PMID 17910045 2008 Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.

PMID 26372703 2015 Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.

PMID 18594010 2008 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

PMID 20926413 2011 The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.

PMID 19396835 2009 Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations.

PMID 16474404 2006 Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.

PMID 23548132 2013 High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

rs13398721 in LOC101928196;LOC105373458 gene and Non-Small Cell Lung Carcinoma

PMID 23478653 2014 A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.

rs727503093 in LRRC56;HRAS gene and Non-Small Cell Lung Carcinoma

PMID 10716188 2000 Role of the switch II region in the conformational transition of activation of Ha-ras-p21.

PMID 2674130 1989 rac, a novel ras-related family of proteins that are botulinum toxin substrates.

PMID 21779495 2011 Functional specificity of ras isoforms: so similar but so different.

PMID 3004741 1986 Ras p21 proteins with high or low GTPase activity can efficiently transform NIH/3T3 cells.

PMID 6287572 1982 Nucleotide sequence of the p21 transforming protein of Harvey murine sarcoma virus.

PMID 6288698 1982 Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses.

PMID 6287573 1982 Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus.

PMID 3304147 1987 ras genes.

PMID 3283542 1988 The ras gene family and human carcinogenesis.

rs1057519729 in MAP2K1 gene and Non-Small Cell Lung Carcinoma

PMID 7651428 1995 RAS signalling is abnormal in a c-raf1 MEK1 double mutant.

PMID 18632602 2008 We also screened 85 NSCLC cell lines for MEK1 exon 2 mutations; one line (NCI-H1437) harbors a Q56P substitution, a known transformation-competent allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with AZD6244.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 18060073 2007 Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.

PMID 18632602 2008 Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

rs397516981 in MIR4728;ERBB2 gene and Non-Small Cell Lung Carcinoma

PMID 18334834 2008 siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.

PMID 16638863 2006 Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.

PMID 22325357 2012 Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

PMID 22761469 2012 Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

PMID 15753357 2005 Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

PMID 15457249 2004 Lung cancer: intragenic ERBB2 kinase mutations in tumours.

rs55768116 in MPZL3 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs11554290 in NRAS gene and Non-Small Cell Lung Carcinoma

PMID 14508525 2003 BRAF mutations in papillary carcinomas of the thyroid.

PMID 22773810 2012 Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

PMID 19880792 2010 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

PMID 23515407 2013 Characteristics of lung cancers harboring NRAS mutations.

PMID 18948947 2008 Somatic mutations affect key pathways in lung adenocarcinoma.

PMID 1654209 1991 ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 6587382 1984 Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.

PMID 24370118 2014 Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.

PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

rs4236709 in NRG1 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs11080466 in PIEZO2 gene and Non-Small Cell Lung Carcinoma

PMID 21866343 2012 The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.

rs104886003 in PIK3CA gene and Non-Small Cell Lung Carcinoma

PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 19029981 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 16930767 2006 PIK3CA mutation status in Japanese lung cancer patients.

PMID 19513541 2009 A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 21430269 2011 Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 16906227 2006 Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

PMID 15016963 2004 High frequency of mutations of the PIK3CA gene in human cancers.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs121909219 in PTEN gene and Non-Small Cell Lung Carcinoma

PMID 20881644 2010 Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.

PMID 20085938 2010 The PI3K pathway as drug target in human cancer.

PMID 10555148 1999 Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

PMID 20018398 2010 PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

PMID 19351834 2009 PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

PMID 11504908 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

PMID 9598803 1998 Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.

rs1571228 in SAXO1 gene and Non-Small Cell Lung Carcinoma

PMID 23144319 2013 Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.

rs1057519858 in STK11 gene and Non-Small Cell Lung Carcinoma

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs11622887 in SYNE3 gene and Non-Small Cell Lung Carcinoma

PMID 23478653 2014 A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.

rs2293607 in TERC gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs13167280 in TERT gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs11375254 in TP63 gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs12265047 in VTI1A gene and Non-Small Cell Lung Carcinoma

PMID 31326317 2019 Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

rs17152930 in XKR6 gene and Non-Small Cell Lung Carcinoma

PMID 21866343 2012 The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.

rs2131877 in XXYLT1 gene and Non-Small Cell Lung Carcinoma

PMID 20876614 2010 A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population.